Northwest Bioth Cmn (NWBO)

$NWBO lol, Merck isn’t going to do any business with NWBO.

$NWBO … NO .. CHOICE … part 7 …

$NWBO part 2 Let’s say you have 12,000 people a year in the UK that could potentially use this treatment at around $200,000 per person. That is around 2.4 billion a year. Divide that by approximately 1.44 billion shares and you come up with just a straight cash value of $1.66 a share but wait. Stocks always traded multiples called a PE ratio. Let’s just take a conservative P/E ratio of 20. You would be looking at a price around $33.20 a share. That does not include the people in the United States that does not include pets that does not include other cancers that this could be applicable for. This is one of those “once in a lifetime stocks.” That is why people are trying to convince you to sell it like at $1 $2 $3 dollars. Believe me, the big boys know the potential of this. I mean you do you and I’ll do me, but I just don’t want you to underestimate the potential here because of nefarious characters.

$NWBO part 1 I just wanna give a reality check for those like myself who are invested in NWBO, and what a potential price target could look like. I understand there’s people who financially cannot wait very long, and then there’s people like me that plan on going the distance. Short hedge funds, market makers, corrupt brokers, and those that want to pick up massive blocks of shares for a cheap price before the whole world figures out what’s going on are counting on the people who want to hit a few dollars and get out quickly. Why do you think there’s people on here constantly trying to undermine the price convincing you that the highest it will go is like $2.00?? Think about this logically. You have a company like NWBO that has extended the lives of people with brain tumors several of which are still alive after 10 years, not to mention how this vaccine could be helpful to other types of solid tumor cancers. Let’s just focus on brain cancer for a moment.

$NWBO https://x.com/alphavestcap/status/1949502435199738123?s=61

$NWBO does LP care about the investors?

$NWBO $NWBO $CYDY in combination with Keytruda. DCVax-L has been shown to prolong the lives of glioblastoma patients in a Phase III trial, both as a standalone treatment and when combined with temozolomide chemotherapy. CYDY (leronlimab): Leronlimab is currently being trialed in combination with Keytruda in a breast cancer xenograft model. Leronlimab has shown potential in metastatic triple-negative breast cancer (mTNBC), with improved progression-free survival (PFS) and overall survival (OS) when used as a monotherapy or in higher doses in a pooled analysis of three clinical trials. The median PFS was 3.8 months, with OS of 6.6 months, and for higher doses, PFS extended to 6.1 months and OS exceeded 12 months. However, this data is not in combination with Keytruda.

$NWBO UK regulatory approval would be a major milestone — not just for NWBO as a company, but for patients worldwide, especially those battling cancers with limited treatment options. It could open the door for broader access, additional trials, and possibly approvals in other regions like the EU or U.S. What matters most, though, is that the science continues to progress and that regulators evaluate it fairly and rigorously. If NWBO's treatment proves safe and effective — especially for a cancer with so few good options and thats exactly why im invested in NWBO its not about the money its all about having compassion for humanity, non of us are exempted from cancer — it deserves to be approved. And those hoping it fails for selfish reasons will be on the wrong side of history.

$NWBO GLTA Here is a little insite to the MERCK NWBO Phase 2 Trial that was Stopped and did Obtain a OS OF 60% The Phase II trial combining DCVax-L and Keytruda did report overall survival (OS) of 60% at a notable checkpoint—though the publicly available details are sparse and underreported. Here’s what we can piece together: - 📈 Clinical signal: The 60% OS suggests significant synergy between DCVax-L’s dendritic cell priming and Keytruda’s checkpoint inhibition. For metastatic colorectal cancer—especially with liver involvement—that kind of outcome exceeds historical norms. - 🧪 Biological plausibility: The trial was built on solid immunologic rationale. DCVax-L boosts T-cell activation and tumor antigen visibility, while Keytruda disrupts PD-1-mediated immune suppression. Together, they offer a powerful one-two punch. - 🛑 Trial cessation: Despite promising OS, the study was not expanded, published in full, or brought to Phase III. Whether that’s due to funding constraints, strategic pivoting, or unpublished safety signals is unclear. NWBO hasn’t made formal statements, and Merck hasn’t referenced the trial in recent immuno-oncology pipeline disclosures. The DCVax-L + Keytruda + Hiltonol trial for metastatic colorectal cancer was indeed registered as NCT03952735, and it included a published chart showing 60% overall survival (OS). But here’s the twist: the entire listing was later scrubbed from ClinicalTrials.gov, leaving no trace—not even in the Wayback Machine or NIH’s internal AACT archive. Here’s what we know: - 🧾 Valid NCT number: The existence of NCT03952735 confirms it was officially registered. NCT numbers aren’t placeholders—they’re only issued after formal submission. - 🌍 Voluntary listing: Because the trial was conducted in Germany and not under an FDA IND, it wasn’t legally required to be listed in the U.S. registry. NWBO and Merck chose to disclose it—likely to signal collaboration and transparency. - Strategic deletion: The trial wasn’t marked “withdrawn” or “terminated.” It was fully erased, which requires a sponsor-initiated request. That kind of removal is rare and suggests intentional suppression, possibly due to IP concerns, unexpected efficacy signals, or strategic timing. - 📊 The chart: While the full publication was pulled, investor forums and archived presentations referenced a chart showing 60% OS, which is extraordinary for MSS colorectal cancer with liver mets. That kind of signal would normally trigger expansion—unless someone wanted to keep it quiet. This trial may be the most underappreciated breadcrumb in NWBO’s regulatory saga. You have to ask yourself why with OS OF 60% WAS IT PULLED ?

$NWBO …. WhAT …. MERCK …. has done in secrecy IS to be relevant in the future ……….